discuss emerging research and actual patients with
TRANSCRIPT
![Page 1: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/1.jpg)
Cases from the Community: Investigators Discuss Emerging Research and Actual Patients
with Gastroesophageal Cancers (Part 2 of a 3-Part Series)
Thursday, February 4, 20215:00 PM – 6:30 PM ET
Daniel Catenacci, MDYelena Y Janjigian, MD
Rutika Mehta, MD, MPHZev Wainberg, MD, MSc
ModeratorNeil Love, MD
Faculty
![Page 2: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/2.jpg)
Faculty
Daniel Catenacci, MDAssociate Professor, Department of MedicineSection of Hematology and OncologyDirector, Interdisciplinary Gastrointestinal Oncology ProgramAssistant Director, Translational ResearchComprehensive Cancer CenterThe University of Chicago Medical Center and Biological SciencesChicago, Illinois
Yelena Y Janjigian, MDAssociate Attending PhysicianAssociate Professor, Weill Cornell Medical CollegeChief, Gastrointestinal Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New York
Rutika Mehta, MD, MPHAssistant Member in the Department of Gastrointestinal OncologyMoffitt Cancer CenterAssistant Professor in the Department of Oncologic SciencesUniversity of South FloridaTampa, Florida
Zev Wainberg, MD, MScCo-Director, GI Oncology ProgramDirector of Early Phase Clinical ResearchJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, California
![Page 3: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/3.jpg)
Commercial Support
This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Lilly and Taiho Oncology Inc.
![Page 4: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/4.jpg)
Dr Love — Disclosures
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc,Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA,ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
![Page 5: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/5.jpg)
Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
![Page 6: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/6.jpg)
Dr Catenacci — Disclosures
Advisory Committee Astellas, Merck, Seagen Inc, Tempus
Consulting Agreements
Amgen Inc, Archer Pharmaceuticals, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gritstone Oncology, Guardant Health, Lilly, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Seagen Inc, Taiho Oncology Inc, Tempus, Zymeworks
Contracted Research Amgen Inc, Genentech, a member of the Roche Group
Data and Safety Board Genentech, a member of the Roche Group, Merck Serono
Speakers Bureau Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Tempus
![Page 7: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/7.jpg)
Dr Janjigian — Disclosures
Consulting Agreements
AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Imugene, Lilly, Merck, Merck Serono, Pfizer Inc, Rgenix, Zymeworks
Contracted ResearchBayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Merck, Rgenix
Ownership Interest (Stock Options) Rgenix
![Page 8: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/8.jpg)
Dr Mehta — Disclosures
Advisory Committee Bristol-Myers Squibb Company, Taiho Oncology Inc
Consulting Agreement Lilly
Science Review Committee NCCN
![Page 9: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/9.jpg)
Dr Wainberg — Disclosures
Consulting Agreements
Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates
Contracted Research Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc
Data and Safety Monitoring Board/Committee Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc
![Page 10: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/10.jpg)
We Encourage Clinicians in Practice to Submit Questions
Feel free to submit questions now before the program begins and throughout the program.
![Page 11: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/11.jpg)
Familiarizing Yourself with the Zoom InterfaceHow to answer poll questions
When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.
![Page 12: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/12.jpg)
![Page 13: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/13.jpg)
Meet The ProfessorManagement of Lung Cancer
Friday, February 5, 202112:00 PM – 1:00 PM ET
Joshua Bauml, MD
ModeratorNeil Love, MD
Faculty
![Page 14: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/14.jpg)
Year in Review — Clinical Investigators Provide Perspectives on the Most Relevant New
Publications, Data Sets and Advances in Oncology:Breast Cancer
Tuesday, February 9, 20215:00 PM – 6:00 PM ET
Harold Burstein, MDLisa Carey, MD
ModeratorNeil Love, MD
Faculty
![Page 15: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/15.jpg)
Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and
Presentations from the 62nd ASH Annual Meeting Part 3 — Multiple Myeloma
Wednesday, February 10, 20215:00 PM – 6:00 PM ET
Rafael Fonseca, MDRobert Z Orlowski, MD, PhDEdward A Stadtmauer, MD
ModeratorNeil Love, MD
Faculty
![Page 16: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/16.jpg)
Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Colorectal Cancer (Part 3 of a 3-Part Series)
Thursday, February 11, 20215:00 PM – 6:00 PM ET
Kristen K Ciombor, MD, MSCIEric Van Cutsem, MD, PhD
ModeratorNeil Love, MD
Faculty
![Page 17: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/17.jpg)
![Page 18: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/18.jpg)
Current Concepts and Recent Advances in Oncology: A Daylong Clinical Summit Hosted in Partnership with
North Carolina Oncology Association (NCOA) and South Carolina Oncology Society (SCOS)
Saturday, February 13, 20218:30 AM – 4:30 PM ET
ModeratorNeil Love, MD
FacultyCourtney D DiNardo, MD, MSCE
Robert Dreicer, MD, MSJustin F Gainor, MD
Sara Hurvitz, MDIan E Krop, MD, PhD
John M Pagel, MD, PhDAlexander Perl, MD
Daniel P Petrylak, MDPhilip A Philip, MD, PhD, FRCP
Paul G Richardson, MD
Mitchell R Smith, MD, PhDEric Van Cutsem, MD, PhD
Peter Voorhees, MDHeather Wakelee, MD
![Page 19: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/19.jpg)
Saturday, February 13, 2021 — 8:30 AM – 4:30 PM
Chronic Lymphocytic Leukemia and Lymphomas: John Pagel, Mitchell Smith
Multiple Myeloma: Paul Richardson, Peter Voorhees
Genitourinary Cancers: Robert Dreicer, Daniel Petrylak
Lung Cancer: Justin Gainor, Heather Wakelee
Gastrointestinal Cancers: Philip Philip, Eric Van Cutsem
Breast Cancer: Sara Hurvitz, Ian Krop
Acute Myeloid Leukemia and Myelodysplastic Syndromes: Courtney DiNardo, Alexander Perl
![Page 20: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/20.jpg)
Thank you for joining us!
CME credit information will be emailed to each participant within 3 business days.
![Page 21: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/21.jpg)
![Page 22: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/22.jpg)
![Page 23: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/23.jpg)
![Page 24: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/24.jpg)
![Page 25: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/25.jpg)
![Page 26: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/26.jpg)
![Page 27: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/27.jpg)
![Page 28: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/28.jpg)
![Page 29: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/29.jpg)
![Page 30: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/30.jpg)
![Page 31: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/31.jpg)
![Page 32: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/32.jpg)
Cases from the Community: Investigators Discuss Emerging Research and Actual Patients
with Gastroesophageal Cancers (Part 2 of a 3-Part Series)
Thursday, February 4, 20215:00 PM – 6:30 PM ET
Daniel Catenacci, MDYelena Y Janjigian, MD
Rutika Mehta, MD, MPHZev Wainberg, MD, MSc
ModeratorNeil Love, MD
Faculty
![Page 33: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/33.jpg)
Faculty
Daniel Catenacci, MDAssociate Professor, Department of MedicineSection of Hematology and OncologyDirector, Interdisciplinary Gastrointestinal Oncology ProgramAssistant Director, Translational ResearchComprehensive Cancer CenterThe University of Chicago Medical Center and Biological SciencesChicago, Illinois
Yelena Y Janjigian, MDAssociate Attending PhysicianAssociate Professor, Weill Cornell Medical CollegeChief, Gastrointestinal Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New York
Rutika Mehta, MD, MPHAssistant Member in the Department of Gastrointestinal OncologyMoffitt Cancer CenterAssistant Professor in the Department of Oncologic SciencesUniversity of South FloridaTampa, Florida
Zev Wainberg, MD, MScCo-Director, GI Oncology ProgramDirector of Early Phase Clinical ResearchJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, California
![Page 34: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/34.jpg)
We Encourage Clinicians in Practice to Submit Questions
You may submit questions using the Zoom Chat
option below
Feel free to submit questions now before the program begins and throughout the program.
![Page 35: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/35.jpg)
Familiarizing Yourself with the Zoom InterfaceHow to answer poll questions
When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.
![Page 36: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/36.jpg)
![Page 37: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/37.jpg)
Meet The ProfessorManagement of Lung Cancer
Friday, February 5, 202112:00 PM – 1:00 PM ET
Joshua Bauml, MD
ModeratorNeil Love, MD
Faculty
![Page 38: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/38.jpg)
Year in Review — Clinical Investigators Provide Perspectives on the Most Relevant New
Publications, Data Sets and Advances in Oncology:Breast Cancer
Tuesday, February 9, 20215:00 PM – 6:00 PM ET
Harold Burstein, MDLisa Carey, MD
ModeratorNeil Love, MD
Faculty
![Page 39: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/39.jpg)
Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and
Presentations from the 62nd ASH Annual Meeting Part 3 — Multiple Myeloma
Wednesday, February 10, 20215:00 PM – 6:00 PM ET
Rafael Fonseca, MDRobert Z Orlowski, MD, PhDEdward A Stadtmauer, MD
ModeratorNeil Love, MD
Faculty
![Page 40: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/40.jpg)
Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Colorectal Cancer (Part 3 of a 3-Part Series)
Thursday, February 11, 20215:00 PM – 6:00 PM ET
Kristen K Ciombor, MD, MSCIEric Van Cutsem, MD, PhD
ModeratorNeil Love, MD
Faculty
![Page 41: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/41.jpg)
![Page 42: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/42.jpg)
Current Concepts and Recent Advances in Oncology: A Daylong Clinical Summit Hosted in Partnership with
North Carolina Oncology Association (NCOA) and South Carolina Oncology Society (SCOS)
Saturday, February 13, 20218:30 AM – 4:30 PM ET
ModeratorNeil Love, MD
FacultyCourtney D DiNardo, MD, MSCE
Robert Dreicer, MD, MSJustin F Gainor, MD
Sara Hurvitz, MDIan E Krop, MD, PhD
John M Pagel, MD, PhDAlexander Perl, MD
Daniel P Petrylak, MDPhilip A Philip, MD, PhD, FRCP
Paul G Richardson, MD
Mitchell R Smith, MD, PhDEric Van Cutsem, MD, PhD
Peter Voorhees, MDHeather Wakelee, MD
![Page 43: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/43.jpg)
Saturday, February 13, 2021 — 8:30 AM – 4:30 PM
Chronic Lymphocytic Leukemia and Lymphomas: John Pagel, Mitchell Smith
Multiple Myeloma: Paul Richardson, Peter Voorhees
Genitourinary Cancers: Robert Dreicer, Daniel Petrylak
Lung Cancer: Justin Gainor, Heather Wakelee
Gastrointestinal Cancers: Philip Philip, Eric Van Cutsem
Breast Cancer: Sara Hurvitz, Ian Krop
Acute Myeloid Leukemia and Myelodysplastic Syndromes: Courtney DiNardo, Alexander Perl
![Page 44: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/44.jpg)
Cases from the Community: Investigators Discuss Emerging Research and Actual Patients
with Gastroesophageal Cancers (Part 2 of a 3-Part Series)
Thursday, February 4, 20215:00 PM – 6:30 PM ET
Daniel Catenacci, MDYelena Y Janjigian, MD
Rutika Mehta, MD, MPHZev Wainberg, MD, MSc
ModeratorNeil Love, MD
Faculty
![Page 45: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/45.jpg)
Warren S Brenner, MDLynn Cancer InstituteBoca Raton, Florida
Ranju Gupta, MDAttending PhysicianCo-Director, Cardio-Oncology programLVPG Hematology Oncology AssociatesLehigh Valley Health Network Bethlehem, Pennsylvania
Maria Regina Flores, MDPhysician Partner for Florida Cancer Specialists and Research InstituteOrlando, Florida
![Page 46: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/46.jpg)
Neil Morganstein, MDHematology OncologyAtlantic Health SystemSummit, New Jersey
Laurie Matt-Amaral, MD, MPHAttending PhysicianCleveland Clinic Akron General Medical CenterAkron, Ohio
Lowell L Hart, MD, FACPScientific Director of ResearchFlorida Cancer Specialists and Research InstituteAssociate Professor of Medicine, Hematology and OncologyWake Forest University School of MedicineWinston-Salem, North CarolinaCo-Director, Phase 1 ProgramWake Forest Baptist Comprehensive Cancer CenterFort Myers, Florida
![Page 47: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/47.jpg)
Agenda
Module 1: Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer
Module 2: Localized and Advanced Esophageal Cancer; Novel Strategies with Immunotherapy in GEJ Cancer
Module 3: Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches
Module 4: Key Optimal Management of HER2-Positive Advanced Gastric/GEJ Cancer
![Page 48: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/48.jpg)
Agenda
Module 1: Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer
Module 2: Localized and Advanced Esophageal Cancer; Novel Strategies with Immunotherapy in GEJ Cancer
Module 3: Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches
Module 4: Key Optimal Management of HER2-Positive Advanced Gastric/GEJ Cancer
![Page 49: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/49.jpg)
Case Presentation – Dr Morganstein: A 61-year-old man with MSS metastatic GEJ cancer – PD-L1 CPS = 2
• History of glioblastoma multiforme over 5 years ago- Long-term treatment with temozolomide - NED
• Presents with 20-pound weight loss- Diagnosed with widespread metastatic GEJ adenocarcinoma
• Undergoing CyberKnife® for three brain metastases
Questions• What is the optimal first-line therapy for this patient? Would the faculty use an
immune checkpoint inhibitor with chemotherapy? If so, what CPS is required?• What is the difference between TPS and CPS? How do we interpret and utilize
that information as to if and when to use immunotherapies?• How would the faculty manage the brain metastases?
Neil Morganstein, MD
![Page 50: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/50.jpg)
Case Presentation – Dr Brenner: An 81-year-old man with MSS metastatic esophageal cancer – PD-L1 TPS 15
• 11/2018: Diagnosed with HER2 negative, MSS, PD-L1 positive (TPS = 15) disease
• 12/2018: FOLFOX x 9 à infusional 5-FU maintenance
• 3/2020: Recurrent disease with brain metastases treated with CyberKnife
• 11/2020: Progressive lower esophageal disease
• 12/2020: Dose modified FOLFOX; addition of nivolumab 1/2021
Questions• Where should we use immunotherapy? Should we administer it with frontline
chemotherapy if PD-L1 >5? Should we use without chemo if PD-L1 >10?• Do we differentiate between squamous cell carcinoma and adenocarcinoma as it
relates to PD-L1 and checkpoint inhibitor therapy?
Warren Brenner, MD
![Page 51: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/51.jpg)
Regulatory and reimbursement issues aside, in which line of therapy if any would you generally recommend an anti-PD-1/PD-L1 antibody (with or without chemotherapy) for a 65-year-old patient with metastatic HER2-negative, MSS adenocarcinoma of the GEJ with a PD-L1 CPS of 0%?
1. First line2. Second line3. Third line4. Beyond third line5. I would not recommend an anti-PD-1/PD-L1 antibody
![Page 52: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/52.jpg)
Regulatory and reimbursement issues aside, in which line of therapy would you generally recommend an anti-PD-1/PD-L1 antibody (with or without chemotherapy) for a 65-year-old patient with metastatic HER2-negative, MSS adenocarcinoma of the GEJ with a PD-L1 CPS of 10%?
1. First line2. Second line3. Third line4. Beyond third line5. I would not recommend an anti-PD-1/PD-L1 antibody
![Page 53: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/53.jpg)
Regulatory and reimbursement issues aside, in which line of therapy would you generally recommend an anti-PD-1/PD-L1 antibody (with or without chemotherapy) for a 65-year-old patient with metastatic HER2-negative, MSI-high adenocarcinoma of the GEJ?
1. First line2. Second line3. Third line4. Beyond third line5. I would not recommend an anti-PD-1/PD-L1 antibody
![Page 54: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/54.jpg)
Regulatory and reimbursement issues aside, in which line of therapy if any would you generally recommend an anti-PD-1/PD-L1 antibody (with or without chemotherapy) for a 65-year-old patient with metastatic HER2-negative, MSS squamous cell carcinoma of the esophagus with a PD-L1 CPS of 0%?
1. First line2. Second line3. Third line4. Beyond third line5. I would not recommend an anti-PD-1/PD-L1 antibody
![Page 55: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/55.jpg)
Regulatory and reimbursement issues aside, in which line of therapy would you generally recommend an anti-PD-1/PD-L1 antibody (with or without chemotherapy) for a 65-year-old patient with metastatic HER2-negative, MSS squamous cell carcinoma of the esophagus with a PD-L1 CPS of 10%?
1. First line2. Second line3. Third line4. Beyond third line5. I would not recommend an anti-PD-1/PD-L1 antibody
![Page 56: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/56.jpg)
Regulatory and reimbursement issues aside, what adjuvant systemic therapy would you currently recommend to a patient with HER2-negative, MSS adenocarcinoma of the GEJ (PD-1 >1) who receives neoadjuvant FLOT and has residual disease at surgery?
1. Anti-PD-1/PD-L1 monotherapy2. Anti-PD-1/PD-L1 and anti-CTLA-4 combination 3. Chemotherapy 4. Chemotherapy followed by anti-PD-1/PD-L1 monotherapy5. I would not recommend adjuvant systemic therapy6. Other
![Page 57: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/57.jpg)
Slide 1
Presented By Zev Wainberg at 2021 Gastrointestinal Cancers Symposium
![Page 58: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/58.jpg)
Bemarituzumab is an IgG1 antibody specific for the FGFR2b Receptor
Presented By Zev Wainberg at 2021 Gastrointestinal Cancers Symposium
![Page 59: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/59.jpg)
FIGHT Trial Design
Presented By Zev Wainberg at 2021 Gastrointestinal Cancers Symposium
![Page 60: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/60.jpg)
Progression-Free Survival and Overall Survival: Intent to Treat
Presented By Zev Wainberg at 2021 Gastrointestinal Cancers Symposium
![Page 61: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/61.jpg)
Best % Change in Target Lesions from Baseline
Presented By Zev Wainberg at 2021 Gastrointestinal Cancers Symposium
![Page 62: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/62.jpg)
FIGHT: Corneal-Related Adverse Events
1 If any event reported, examinations were to continue every 8W until resolution, even if drug discontinued 2 SMQ = Standardised MedDRA Query3 Most common: dry eye (26.3%), keratitis (15.8%), punctate keratitis (14.5%), vision blurred (15.0%), corneal epithelium defect (10.5%)4 No ≥ grade 4 event reported5 Most common: dry eye (n=4), keratitis (n=4), corneal disorder (n=2), eye disorder (n=2) limbal stem cell deficiency (n=2), punctate keratitis (n=2)
Bema (N = 76) Placebo (N = 77)
Corneal Adverse Events (SMQ)2 All Grade3 51 (67.1%) 8 (10.4%)
Corneal Adverse Events (SMQ) Grade 34 18 (23.7%) 0
Median time to onset to any grade, weeks (range) 16.1(0.1, 41.0)
11.6(6.0, 29.0)
Corneal AE leading to bema/placebo discontinuation5 20 (26.3%) 0
AE resolved 12 (60.0%) 0
AE not resolved as of 23 Sept 2020 8 (40.0%) 0
Median time to resolution, weeks (95%CI) 27.0(18.9, NR) NA
Trial required corneal evaluation at baseline and every 8 weeks until the end of treatment1
Courtesy of Daniel Catenacci, MD
![Page 63: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/63.jpg)
Pembrolizumab plus Chemotherapy for Previously Untreated, HER2-Negative Unresectable or Metastatic Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma: KEYNOTE-859.
Tabernero J et al.Gastrointestinal Cancers Symposium 2021;Abstract TPS263.
![Page 64: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/64.jpg)
KEYNOTE-859: Study Design and Key Outcomes
Tabernero J et al. Gastrointestinal Cancers Symposium 2021;Abstract TPS263.
Primary Outcomes: OS, PFSSecondary Outcomes: ORR, DoR, safety/tolerability
![Page 65: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/65.jpg)
Courtesy of Yelena Y Janjigian, MD
![Page 66: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/66.jpg)
• Superior OS, 29% reduction in the risk of death, and a 3.3-month improvement in median OS with NIVO + chemo versus chemo in patients whose tumors expressed PD-L1 CPS ≥ 5
CheckMate 649
Overall survival: CheckMate 649
aMinimum follow-up 12.1 months.
Primary endpoint (PD-L1 CPS ≥ 5)
NIVO + chemo(n = 473)
Chemo(n = 482)
Median OS, mo 14.4 11.1
(95% CI) (13.1–16.2) (10.0–12.1)
HR (98.4% CI) 0.71 (0.59–0.86)
P value < 0.0001
OS
(%)a
NIVO + chemo
Chemo
MonthsNo. at riskNIVO + chemo 473 438 377 313 261 198 149 96 65 33 22 9 1 0Chemo 482 421 350 271 211 138 98 56 34 19 8 2 0 0
0
20
40
60
80
10012-morate
57%
46%
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Courtesy of Yelena Y Janjigian, MD
![Page 67: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/67.jpg)
KEY DIFFERENCES: KEYNOTE-062 VS. CheckMate 649
Courtesy of Yelena Y Janjigian, MD
![Page 68: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/68.jpg)
ATTRACTION-4: Progression-Free Survival(Interim Analysis)
Cut off: 31 Oct 2018 for Interim analysis
Nivolumab + chemotherapy
N = 362
Placebo + chemotherapy
N = 362Median PFS, months(95% CI)
10.45(8.44-14.75)
8.34(6.97-9.40)
Hazard ratio(98.51% CI)
0.68(0.51 – 0.90)
P value 0.00071yr PFS rate (%) 45.4 30.6
• PFS was continuously longer in NIVO + Chemo than in Chemo at the final analysis(NIVO+Chemo vs. Chemo: HR 0.70; mPFS 10.9 vs. 8.4 mo)
Courtesy of Yelena Y Janjigian, MD
![Page 69: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/69.jpg)
Agenda
Module 1: Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer
Module 2: Localized and Advanced Esophageal Cancer; Novel Strategies with Immunotherapy in GEJ Cancer
Module 3: Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches
Module 4: Key Optimal Management of HER2-Positive Advanced Gastric/GEJ Cancer
![Page 70: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/70.jpg)
Case Presentation – Dr Gupta: A 63-year-old woman with MSS metastatic gastric cancer – TMB 19 mut/Mb, PD-L1 CPS 0• 2018: Diagnosed with T3, LN negative, proximal stomach adenocarcinoma • NGS: PD-L1 negative | TMB: 19 muts/Mb | CPS: 0 | MSS• FLOT x 4 à surgery à FLOT x 4 for residual disease• 8/2019: Developed peritoneal metastases • Ramucirumab/paclitaxel à disease progression 2 months later• Pembrolizumab x 2 cycles
Questions• Could we have used first-line pembrolizumab here? Would the faculty have chosen a
different second-line therapy give the TMB? What other treatment options would they consider if the patient experienced disease progression on pembrolizumab?
• POLE gene variant as potential marker of ICI benefit?
Ranju Gupta, MD
![Page 71: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/71.jpg)
Case Presentation – Dr Flores: A 53-year-old Hispanic woman with gastric cancer
• Presented with ulcerated antral mass and 20-pound weight loss
• Pathology indicates adenocarcinoma; molecular profiling is pending
• Potential therapy: FLOT
Questions• What neoadjuvant chemotherapy would the faculty utilize?• If the patient develops metastatic disease, what is your approach if she were not a
candidate for surgery?• Is there a difference in how you treat squamous cell esophageal cancer versus
adenocarcinoma? Is there a difference as far as the role of immunotherapy or other therapies?
Maria Flores, MD
![Page 72: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/72.jpg)
CheckMate 577: Health-related quality of life in a randomized, double-blind phase 3 study of nivolumab versus placebo as adjuvant treatment in patients with resected esophageal cancer or gastroesophageal junction cancer
Presented By Eric Van Cutsem at 2021 Gastrointestinal Cancers Symposium
![Page 73: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/73.jpg)
Patient-Reported Outcome (PRO) Administration Schedule in CheckMate 577
Presented By Eric Van Cutsem at 2021 Gastrointestinal Cancers Symposium
![Page 74: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/74.jpg)
CheckMate 577: Adjuvant Nivolumab Following Neoadjuvant CRT/Resection in Esophageal/GEJ Cancer
Kelly. ESMO 2020. Abstr LBA9.
§ Randomized phase III trial of adjuvant nivolumab vs placebo following neoadjuvant CRT + surgical resection* for pts with stage II/III esophageal/GEJ adenocarcinoma/SCC (N = 794)
DFS (Primary Endpoint)
*Residual pathologic disease ≥ ypT1 or ≥ ypN1.
100
80
60
40
20
00 3 6b 9 12 15 18 21 24 27 30 33 36 39 42 45
Months
DFS(
%)
Nivolumab
Placebo
Median DFS, Mos (95% CI)Nivolumab (n = 532) 22.4 (16.6 – 34.0)Placebo (n = 262) 11.0 (8.3 – 14.3)HR: 0.69 (96.4% CI: 0.56 – 0.86; P = .0003)
Courtesy of Zev Wainberg, MD, MSc
![Page 75: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/75.jpg)
Conclusion
Presented By Eric Van Cutsem at 2021 Gastrointestinal Cancers Symposium
![Page 76: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/76.jpg)
Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: <br />DELIVER trial (JACCRO GC-08)
Presented By Yu Sunakawa at 2021 Gastrointestinal Cancers Symposium
![Page 77: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/77.jpg)
Results:
Presented By Yu Sunakawa at 2021 Gastrointestinal Cancers Symposium
![Page 78: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/78.jpg)
LEAP-005: A Phase 2 Multicohort Study of Lenvatinib Plus Pembrolizumab in Patients With Previously Treated Selected Solid Tumors: Results From the Gastric Cancer Cohort
Presented By Hyun Chung at 2021 Gastrointestinal Cancers Symposium
![Page 79: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/79.jpg)
LEAP-005 (NCT03797326)<br />Gastric Cancer Cohort
Presented By Hyun Chung at 2021 Gastrointestinal Cancers Symposium
![Page 80: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/80.jpg)
Antitumor Activity<br />(Confirmed Objective Responses, RECIST v1.1 by BICR)
Presented By Hyun Chung at 2021 Gastrointestinal Cancers Symposium
![Page 81: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/81.jpg)
Health-Related Quality of Life of Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study
Presented By Wasat Mansoor at 2021 Gastrointestinal Cancers Symposium
![Page 82: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/82.jpg)
KEYNOTE-590 Study Design (NCT03189719) and Primary Study Results
Presented By Wasat Mansoor at 2021 Gastrointestinal Cancers Symposium
![Page 83: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/83.jpg)
KEYNOTE-590 – Overall Survival in All Patients
Kato K, et al. ESMO 2020. Abstract LBA8 Courtesy of Zev Wainberg, MD, MSc
![Page 84: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/84.jpg)
KEYNOTE-590 – Overall Survival in SCC Patients
Kato K, et al. ESMO 2020. Abstract LBA8 Courtesy of Zev Wainberg, MD, MSc
![Page 85: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/85.jpg)
Conclusions
Presented By Wasat Mansoor at 2021 Gastrointestinal Cancers Symposium
![Page 86: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/86.jpg)
Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum<br />of 5-year follow-up
Presented By Ken Kato at 2021 Gastrointestinal Cancers Symposium
![Page 87: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/87.jpg)
ATTRACTION-1: Efficacy
Presented By Ken Kato at 2021 Gastrointestinal Cancers Symposium
![Page 88: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/88.jpg)
Conclusions
Presented By Ken Kato at 2021 Gastrointestinal Cancers Symposium
![Page 89: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/89.jpg)
Three-Year Follow-Up of ATTRACTION-3: A Phase III Study of Nivolumab (Nivo) in Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) That Is Refractory or Intolerant to Previous Chemotherapy
Chin K et al.Gastrointestinal Cancers Symposium 2021;Abstract 204.
![Page 90: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/90.jpg)
Nivolumab Chemotherapy P valueOverall Response Rate 19% 22% 0.63Disease Control Rate 37% 63%Median Time to Response 2.6 months 1.5 monthsDuration of Response 6.9 months 3.9 monthsTreatment-Related Adverse Events 66% 95%Dose delays due to Adverse Events 39% 50%
Cho BC et al ESMO 2019 Annual Congress and Kato K et al Lancet Oncology 2019
ATTRACTION-3: Nivolumab in Esophageal Squamous Cell Carcinoma (ESCC)
Courtesy of Zev Wainberg, MD, MSc
![Page 91: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/91.jpg)
ATTRACTION-3: Overall Survival (3-Year Follow-Up)
• No new safety signal was identified with 3-years follow-up and no major late-onset select TRAEs were observed
Chin K et al. Gastrointestinal Cancers Symposium 2021;Abstract 204.
![Page 92: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/92.jpg)
ATTRACTION-3: OS Landmark Analysis at 4 Months by Best Overall Response – Stable Disease
Chin K et al. Gastrointestinal Cancers Symposium 2021;Abstract 204.
![Page 93: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/93.jpg)
ATTRACTION-3: OS Landmark Analysis at 4 Months by Best Overall Response – Progressive Disease
Chin K et al. Gastrointestinal Cancers Symposium 2021;Abstract 204.
![Page 94: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/94.jpg)
Neoadjuvant PD-1 Blockade in Combination with Chemotherapy for Patients with ResectableEsophageal Squamous Cell Carcinoma
Cheng C et al.Gastrointestinal Cancers Symposium 2021;Abstract 220.
![Page 95: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/95.jpg)
Radiographic Response: Neoadjuvant camrelizumab in combination with chemotherapy
![Page 96: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/96.jpg)
Agenda
Module 1: Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer
Module 2: Localized and Advanced Esophageal Cancer; Novel Strategies with Immunotherapy in GEJ Cancer
Module 3: Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches
Module 4: Key Optimal Management of HER2-Positive Advanced Gastric/GEJ Cancer
![Page 97: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/97.jpg)
Case Presentation – Dr Matt-Amaral: A 68-year-old man with metastatic esophageal cancer
• 2017: History of Barrett's esophagus with dysplasia s/p resection- Non-compliant with follow-up
• History of prostate cancer and coronary artery disease
• Fall 2019: Presents with difficulty swallowing, 30 plus pound weight loss
• Suspected Stage IV disease, mostly with liver metastases à FOLFOX
• Potential plan: Liver-directed therapy
Questions• Do the faculty have a specific liver-directed therapy that they feel would be
more beneficial for this patient given his medical history? Or is whatever is available or that insurance would cover appropriate?
Laurie Matt-Amaral, MD, MPH
![Page 98: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/98.jpg)
Regulatory and reimbursement issues aside, what would you currently recommend as second-line therapy for a patient with metastatic HER2-negative, MSS gastric adenocarcinoma who has experienced disease progression on first-line FOLFOX?
1. Ramucirumab2. Ramucirumab/paclitaxel 3. Other chemotherapy 4. Test for PD-L1 CPS and administer pembrolizumab if ≥15. Test for PD-L1 CPS and administer pembrolizumab if ≥10 6. Pembrolizumab 7. Nivolumab8. Other
![Page 99: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/99.jpg)
What is your usual third-line treatment for a younger patient (PS 0) with metastatic HER2-negative, MSS gastric cancer (PD-L1 CPS <1) who has experienced disease progression on FOLFOX and paclitaxel/ramucirumab?
1. TAS-1022. Other chemotherapy 3. Nivolumab4. Pembrolizumab5. Palliative care6. Other
![Page 100: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/100.jpg)
Trifluridine/Tipiracil Outcomes in Third or Later Lines versus Placebo in Metastatic Gastric Cancer Treatment: An Exploratory Subgroup Analysis from the TAGS Study
Tabernero J et al.Gastrointestinal Cancers Symposium 2021;Abstract 229.
![Page 101: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/101.jpg)
TAGS Exploratory Subgroup Analysis: Median OS in the ITT Population
Tabernero J et al. Gastrointestinal Cancers Symposium 2021;Abstract 229.
![Page 102: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/102.jpg)
A Phase Ib Multicenter Study of Trifluridine/Tipiracil(FTD/TPI) in Combination with Irinotecan (IRI) in Patients with Advanced Recurrent or Unresectable Gastric and Gastroesophageal Adenocarcinoma (Agec) After at Least One Line of Treatment with a Fluoropyrimidine and Platinum Containing Regimen
Dayyani F et al.Gastrointestinal Cancers Symposium 2021;Abstract TPS251.
![Page 103: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/103.jpg)
TAS-102 in Combination with Irinotecan: Ongoing Phase Ib Study Design and Objectives
Dayyani F et al. Gastrointestinal Cancers Symposium 2021;Abstract TPS251.
Current Enrollment (n = 20)
Primary Objective:• Regimen feasibility and efficacy
estimate
Secondary Objectives:• Overall survival• Overall response rate• Adverse events
![Page 104: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/104.jpg)
A Phase I/II Trial of Trifluridine/Tipiracil in Combination with Irinotecan in Patients with Advanced Gastric Cancer Refractory to Fluoropyrimidine, Platinum, and Taxane
Hara H et al.Gastrointestinal Cancers Symposium 2021;Abstract 210.
![Page 105: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/105.jpg)
TAS-102 in Combination with Irinotecan: Results from a Phase I/II Study
Hara H et al. Gastrointestinal Cancers Symposium 2021;Abstract 210.
![Page 106: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/106.jpg)
Results of a Phase II Trial of Ramucirumab plus Irinotecan as Second-Line Treatment for Patients with Advanced Gastric Cancer (HGCSG 1603)
Kawamoto Y et al.Gastrointestinal Cancers Symposium 2021;Abstract 217.
![Page 107: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/107.jpg)
HGCSG 1603: Second-Line Ramucirumab plus Irinotecan
Kawamoto Y et al. Gastrointestinal Cancers Symposium 2021;Abstract 217.
![Page 108: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/108.jpg)
Rainbow-Asia: A Randomized, Multicenter, Double-Blind, Phase III Study of Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in the Treatment of Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Following Disease Progression on First-Line Chemotherapy with Platinum and Fluoropyrimidine
Xu R et al.Gastrointestinal Cancers Symposium 2021;Abstract 199.
![Page 109: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/109.jpg)
Xu R et al. Gastrointestinal Cancers Symposium 2021;Abstract 199.
![Page 110: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/110.jpg)
Xu R et al. Gastrointestinal Cancers Symposium 2021;Abstract 199.
![Page 111: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/111.jpg)
Phase II Study of Zolbetuximab plus Pembrolizumab in Claudin 18.2: Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJ) — ILUSTRO Cohort 3
Klempner SJ et al.Gastrointestinal Cancers Symposium 2021;Abstract TPS260.
![Page 112: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/112.jpg)
Zolbetuximab
• It is a first-in-class novel chimeric idealized IgG1 monoclonal antibody
• Targets only tumor cells and has a lower toxicity profile than other anti-cancer monoclonal antibodies
• It activates ADCC and complement-dependent cytotoxicity.
Courtesy of Rutika Mehta, MD, MPH
![Page 113: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/113.jpg)
ILUSTRO Study Design – Target Enrollment (n = 112)
Klempner SJ et al. Gastrointestinal Cancers Symposium 2021;Abstract TPS260.
![Page 114: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/114.jpg)
ILUSTRO Cohort 3 – Target Enrollment (n = 62)
Klempner SJ et al. Gastrointestinal Cancers Symposium 2021;Abstract TPS260.
Cohort 3A (safety cohort):
Primary Endpoint:• Safety/tolerability
Cohort 3B (expansion cohort):
Primary Endpoint: • Overall response rate (ORR) by
IRC
Key Secondary Endpoints:• ORR by INV• Disease control rate• Duration of response• Progression-free survival• Overall survival
![Page 115: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/115.jpg)
Agenda
Module 1: Evolving Front-Line Management of Advanced Gastric/Gastroesophageal Junction (GEJ) Cancer
Module 2: Localized and Advanced Esophageal Cancer; Novel Strategies with Immunotherapy in GEJ Cancer
Module 3: Selection and Sequencing of Therapies for Relapsed Gastric/GEJ Cancer; Novel Investigational Approaches
Module 4: Key Optimal Management of HER2-Positive Advanced Gastric/GEJ Cancer
![Page 116: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/116.jpg)
Case Presentation – Dr Hart: A 52-year-old man with gastric cancer with HER2 and HER3 mutations
• 11/2019: Presented with large 6 cm fungating mass in cardia and gastric fundus
• IHC: HER2 = 1+
• 3/2020: Neoadjuvant FLOT x 6 à total gastrectomy à residual disease
• 5/2050: Adjuvant FLOT
• NGS: ERBB2 and ERBB3 mutations
• 7/2020: FLOT discontinued due to worsening neuropathy; initiated lapatinib
Questions• Should NGS be part of initial work-up? Role for (neo)adjuvant HER2 targeted agents?• Would you use a TKI at all in this setting or use a different one?• If the patient experiences progression, would you consider T-DXd?
Lowell Hart, MD
![Page 117: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/117.jpg)
Case Presentation – Dr Brenner: An 84-year-old man with advanced MSI-high gastric cancer – HER2 activating mutation
• 6/2020: Diagnosed with signet-ring disease with evidence of peritoneal disease and mesenteric lymph nodes
• NGS: MSI-h | high TMB | HER2 and FGFR2 activating mutations | PD-L1 low
• FOLFOX x 8 à disease progression
• Single-agent pembrolizumab
Questions• Would it have been better to start the patient on a checkpoint inhibitor?• What is the significance of HER2 activating mutation?• Should we consider dual checkpoint inhibitor therapy?
Warren Brenner, MD
![Page 118: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/118.jpg)
Regulatory and reimbursement issues aside, in which line of therapy would you generally recommend trastuzumab deruxtecanfor a 65-year-old patient with metastatic HER2-positive, MSS adenocarcinoma of the GEJ?
1. First line2. Second line3. Third line4. Beyond third line5. I would not recommend an anti-PD-1/PD-L1 antibody
![Page 119: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/119.jpg)
A Phase Ib/II, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study Evaluating Trastuzumab Deruxtecan (T-DXd, DS-8201) Monotherapy and Combinations in Patients with HER2-Overexpressing Gastric Cancer (Destiny-Gastric03)
Janjigian YY et al.Gastrointestinal Cancers Symposium 2021;Abstract TPS261.
![Page 120: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/120.jpg)
Janjigian YY et al. Gastrointestinal Cancers Symposium 2021;Abstract TPS261.
A Phase Ib/II, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study Evaluating Trastuzumab Deruxtecan
![Page 121: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/121.jpg)
A Phase Ib/II, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study Evaluating Trastuzumab Deruxtecan
Janjigian YY et al. Gastrointestinal Cancers Symposium 2021;Abstract TPS261.
![Page 122: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/122.jpg)
FDA Approves Trastuzumab Deruxtecan for HER2-Positive Advanced Gastric/GEJ Adenocarcinomas Press Release: January 15, 2021
• The FDA approved trastuzumab deruxtecan for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
• Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01) for patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens, including trastuzumab, a fluoropyrimidine-and a platinum-containing chemotherapy.
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas.
![Page 123: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/123.jpg)
Phase II DESTINY-Gastric01 Trial Design
Shitara K et al. ASCO 2020;Abstract 4513.
Physician’s choice(Irinotecan or paclitaxel) (n = 60)
T-DXd (n = 120)6.4 mg/kg, 3-week cycle
![Page 124: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/124.jpg)
DESTINY-Gastric01 Trial: Third Line – Trastuzumab Deruxtecan
Shitara et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. NEJM 2020
Irinotecan or paclitaxel
N= 125 ptsR 2:1100% Asian
51%
14%
Courtesy of Daniel Catenacci, MD
![Page 125: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/125.jpg)
DESTINY-Gastric01 Trial: Third Line – Trastuzumab Deruxtecan
Shitara et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. NEJM 2020
Irinotecan or paclitaxel
Courtesy of Daniel Catenacci, MD
![Page 126: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/126.jpg)
Ongoing Trials of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Gastric or GEJ Adenocarcinoma
Janjigian YY et al. ESMO 2020;Abstract 1500TiP; Clinicaltrials.gov; Assessed January 2021
Trial name (Identifier) Phase
Target accrual (N) Setting Treatment Arms
DESTINY-Gastric04
(NCT04704934)
III 490 • Unresectable and/or metastatic• Progressed on or after a
trastuzumab-based regimen
• T-DXd• Ramucirumab + paclitaxel
DESTINY-Gastric03
(NCT04379596)
II 220 • Locally advanced, unresectable or metastatic
• Progression on or after at least 1 prior trastuzumab-based regimen – Part 1
• Previously untreated dx – Part 2
Part 1• T-DXd + 5-FU ± oxaliplatin
(Ox)• T-DXd + Cape ± Ox• T-DXd + Durvalumab ± 5-FU
or capePart 2• Trastuzumab + 5-FU or Cape
+ Ox or Cisplatin• T-DXd monotherapy• T-DXd + 5-FU or cape ± Ox• T-DXd + 5-FU or Cape +
Durvalumab
![Page 127: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/127.jpg)
MOUNTAINEER-02: Phase II/III Study of Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma — Trial in Progress
Strickler JH et al.Gastrointestinal Cancers Symposium 2021;Abstract TPS252.
![Page 128: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/128.jpg)
Strickler JH et al. Gastrointestinal Cancers Symposium 2021;Abstract TPS252.
![Page 129: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/129.jpg)
Meet The ProfessorManagement of Lung Cancer
Friday, February 5, 202112:00 PM – 1:00 PM ET
Joshua Bauml, MD
ModeratorNeil Love, MD
Faculty
![Page 130: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/130.jpg)
Current Concepts and Recent Advances in Oncology: A Daylong Clinical Summit Hosted in Partnership with
North Carolina Oncology Association (NCOA) and South Carolina Oncology Society (SCOS)
Saturday, February 13, 20218:30 AM – 4:30 PM ET
ModeratorNeil Love, MD
FacultyCourtney D DiNardo, MD, MSCE
Robert Dreicer, MD, MSJustin F Gainor, MD
Sara Hurvitz, MDIan E Krop, MD, PhD
John M Pagel, MD, PhDAlexander Perl, MD
Daniel P Petrylak, MDPhilip A Philip, MD, PhD, FRCP
Paul G Richardson, MD
Mitchell R Smith, MD, PhDEric Van Cutsem, MD, PhD
Peter Voorhees, MDHeather Wakelee, MD
![Page 131: Discuss Emerging Research and Actual Patients with](https://reader034.vdocument.in/reader034/viewer/2022051315/627a686e1eb8c94146471984/html5/thumbnails/131.jpg)
Thank you for joining us!
CME credit information will be emailed to each participant within 3 business days.